Supplements

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Family Practice News and Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr. Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc., Neurocrine Biosciences, Inc., Pfizer Inc. and Wyeth. He is also on the speaker's bureau for Forest, Pfizer, and Wyeth.

Special Populations in Depression: Managing Care for Patients With Depression and Comorbid Health Problems
Larry Culpepper, MD

Case Files
• Postherpetic Neuralgia
• Diabetes and Pain
Bill McCarberg, MD
Founder. Chronic Pain Management Program
Kaiser Permanente
Escondido, Calif.
Dr. McCarberg has disclosed that he is on the speaker's bureau for Alpharma Inc., Cephalon, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Merck & Co., Inc., Ortho-McNeil Pharmaceutical, Inc., Pfizer Inc., and Pricara.

Practical Bits: Quick and Practical Diagnostic Tools

Clinical Approaches to Patient Concerns About Memory Loss
Richard J. Caselli, MD
Chair, Department of Neurology
Mayo Clinical Scottsdale (Arizona)
Professor of Neurology
Mayo Clinic College of Medicine
Rochester, Minn.
Dr. Caselli disclosed that he has received funding for clinical grants from Arizona Alzheimer's Consortium.

Social and Emotional Costs of Learning Disabilities
Carl C. Bell, MD
Chief Executive Officer and President
Community Mental Health Council Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Applying Cultural Flexibility to Depression in Minority Populations
William B. Lawson, MD, PhD, DFAPA
Professor and Chair
Department of Psychiatry and Behavioral Sciences
Director, Mood Research Program
Howard University College of Medicine and Hospital
Washington, D.C.
Dr Lawson has disclosed that he has received clinical grants from AstraZeneca, the National Institute of Mental Health, and Pfizer Inc., and is a consultant to AstraZeneca and Pfizer.

Resources in the Spotlight

Practical Bits: Quick and Practical Diagnostic Tools

Case File on Seasonal Affective Disorder
David L. Dunner, MD, FACPsychDirector, Center for Anxiety and Depression
Professor Emeritus, Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle, Wash.
Dr Dunner has disclosed that he has received grant support from, is on the advisory board of, and/or on the speaker's bureau of Bristol-Myers Squibb Company, Corcept Therapeutics, Cyberonics, Inc., Cypress Bioscience Inc., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Healthcare Technology Systems, Janssen, L.P., Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer Inc., Roche Diagnostics, Shire Pharmaceuticals Group plc, Somerset Pharmaceuticals, Inc., and Wyeth Pharmaceuticals.

Case File on Depression in Minorities
Peggy L. Johnson, MD
Assistant Professor
Vice Chair for Clinical Services
Department of Psychiatry
Boston University School of Medicine
Boston, Mass.
Dr Johnson has nothing to disclose.

Clinical Approaches to Recognizing and Managing Bipolar Disorder
Andrew J. Cutler, MD
Courtesy Assistant Professor, Department of Psychiatry
University of Florida
President and Medical Director
Florida Clinical Research Center, LLC
Maitland, Fla.
Dr Cutler has disclosed that he has received research grants from Abbott Laboratories Pharmaceutical Product Division, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Cephalon, Inc., Dainippon Sumitomo Pharma Co., Ltd., Eli Lilly and Company, Forest Laboratories, Inc., GlaxoSmithKline, Janssen, L.P., JDS Pharmaceuticals LLC, Johnson & Johnson PRD, Memory Pharmaceuticals, Novartis Pharmaceuticals Corporation, Organon, Otsuka America Pharmaceuticals, Pfizer, Sanofi, Sepracor Inc., Shire Pharmaceuticals Group plc, Solvay Pharmaceuticals, Vanda Pharmaceuticals, and Wyeth Pharmaceuticals. He is a consultant and on the speaker's bureau for Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline,Janssen, Otsuka, Pfizer, Sepracor, Shire, and Vanda. He is also a consultant to Supernus Pharmaceuticals, Inc.

Adults With ADHD Need to Know Treatment Options
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois, Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Effective Approaches to Depression in Men
Michael E. Thase, MD
Professor, Department of Psychiatry
University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center
Philadelphia, Penn.
University of Pittsburgh School of Medicine
Pittsburgh, Penn.
Dr Thase has disclosed that he is a consultant to AstraZeneca, Bristol-Myers Squibb Company, Cephalon, Inc., Cyberonics, Inc, Eli Lilly & Company, GlaxoSmithKline, Janssen L.P., MedAvante, Inc., Neuronetics, Novartis Pharmaceuticals Corporation, Organon, Sepracor Inc., Shire US Inc., Supernus Pharmaceuticals, Inc., and Wyeth. He is on the speakers bureau of AstraZeneca, Bristol-Myers Squibb, Cyberonics, Lilly, GlaxoSmithKline, Organon, sanofi-aventis, and Wyeth.

Practical Bits
Quick and Practical Diagnostic Tools

Resources in the Spotlight

Case Files on Smoking/Myocardial Infarction and Smoking/Gastric Bypass Surgery
Ellen A. Dornelas, PhD
Director of Behavioral Health Programs
Preventive Cardiology
Hartford Hospital
University of Connecticut School of Medicine
Farmington, Conn.
Dr Dornelas has disclosed that she has received clinical grants from Pfizer Inc. Dr Miller has nothing to disclose.

Strategies for Managing Anxiety Disorders
Thomas L. Schwartz, MD
Associate Professor of Psychiatry
Director of Adult Outpatient Services
Director of the Depression and Anxiety Disorders Research Program
Assistant Director of Residency Training
State University of New York (SUNY) Upstate Medical University
Syracuse, N.Y.
Dr Schwartz has disclosed that he has received clinical grants from Wyeth and Forest Laboratories, Inc., and is a consultant to Wyeth.

Cast a Wide Net With Chronic Pain
Carl C. Bell, MD
Chief, Executive Officer and President
Community Mental Health Council, Inc.
Director, Public and Community Psychiatry
University of Illinois
Chicago, Ill.

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

TOPIC HIGHLIGHTS/FACULTY

Letter From Guest Editor
Larry Culpepper, MD, MPH
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.

Special Populations in Depression: Practical Approaches to Depression in Seniors
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding from Eli Lilly and Company. He is a consultant to Eli Lilly and AstraZeneca.

Advances in Assessing and Managing Insomnia
Ellen H. Miller, MD
Clinical Associate Professor of Medicine
Albert Einstein College of Medicine
New York, N.Y.
Private Practice in Internal Medicine and Endocrinology
Hewlett, N.Y.
Dr Miller has nothing to disclose.

Case File: Elderly Man With Insomnia and Depression
Joseph A. Lieberman III, MD, MPH
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

A Multidisciplinary Approach to the Management of Chronic Pain
Rollin M. Gallagher, MD, MPH, DABPM
Director of Pain Management, Department of Anesthesiology
Philadelphia VA Medical Center
Clinical Professor of Psychiatry and Anesthesiology
Director, Center for Pain Medicine, Research and Policy
University of Pennsylvania School of Medicine
Philadelphia, Penn.
Dr Gallagher has nothing to disclose.

Resources in the Spotlight

Practical Bits
Quick and Practical Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

A supplement to Internal Medicine News.

•TOPIC HIGHLIGHTS/FACULTY

Welcome Letter:
From the Publisher

Special Populations in Depression: Recognizing and Managing Depression in Women
Larry Culpepper, MD, MPH, Guest Editor
Chief of Family Medicine
Boston Medical Center
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston, Mass.
Dr Culpepper has disclosed that he is a consultant to Eli Lilly and Company, Forest Laboratories, Inc, Pfizer Inc, and Wyeth.

Case Files on Depression/Insomnia and Chronic Pain/Anxiety/Insomnia
Joseph A. Lieberman III, MD, MPH
Associate Professor of Medicine
Associate Editor, Delaware Medical Journal
Professor of Family Medicine
Jefferson Medical College of Philadelphia
Hockessin, Del.

Management of Disabling Migraine Episodes
Carolyn Bernstein, MD
Assistant Professor of Neurology
Cambridge Hospital
Harvard Medical School
Boston, Mass.
Dr Bernstein has nothing to disclose.

Resources in the Spotlight

Point of View: Challenges in Primary Care Persist Over Time
William Clay Jackson, MD, DipTh
Family Medicine and Palliative Medicine
Memphis, Tenn.
Dr Jackson has received funding for clinical grants from Eli Lilly and Company. He is a consultant to AstraZeneca and Eli Lilly.

Practical Bits: Diagnostic Tools

A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.

•Topic Highlights

To view the supplement, click the image above.

Gastrointestinal Disorders: When to Refer?

Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.

Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.

Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG

Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG

Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.

Recent H. pylori Literature Explores New Questions

A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.

•Topic Highlights

To view the supplement, click the image above.

Gastrointestinal Disorders: When to Refer?

Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.

Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.

Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG

Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG

Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.

Recent H. pylori Literature Explores New Questions

A supplement to Internal Medicine News.
This Clinical Update is supported by Braintree Laboratories, Inc.
The articles are based on interviews with the faculty.

•Topic Highlights

To view the supplement, click the image above.

Gastrointestinal Disorders: When to Refer?

Understanding the Anatomy and Physiology of Constipation
Lawrence R. Schiller, MD, FACP, FACG
Program Director, Gastroenterology Fellowship
Department of Gastroenterology
Baylor University Medical Center
Dallas, TX
Consultant: Braintree Laboratories, Inc. and Novartis Pharmaceuticals. He discusses the unlabeled use of tegaserod for constipation. He also discusses the investigational use of NT-3 for constipation.

Management of Constipation Begins With Attention to Clinical Details
Jack A. DiPalma, MD, FACP, FACG
Professor and Director
Division of Gastroenterology
University of South Alabama College of Medicine
Mobile, AL
Grant/Research Support and Consultant: Braintree Laboratories, Inc.

Recent Clinical Trials Provide Stronger Basis for Constipation Therapy
Lawrence R. Schiller, MD, FACP, FACG

Patients at Opposite Ends of the Age Spectrum Share Clinical Features of Constipation
Jack A. DiPalma, MD, FACP, FACG

Surgical Treatment for Chronic Constipation: Favorable Option in Selected Patients
David E. Beck, MD, FACS
Chairman, Department of Colon and Rectal Surgery
Ochsner Clinical Foundation
New Orleans, LA
Nothing to disclose.

Recent H. pylori Literature Explores New Questions

A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

A supplement to Internal Medicine News.
This CLINICAL UPDATE is supported by Takeda Pharmaceuticals North America, Inc.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Roland R. Griffiths, PhD
Professor of Behavioral Biology
Departments of Psychiatry and Neuroscience
Johns Hopkins University
School of Medicine
Baltimore, Md.
Dr. Griffiths has disclosed that he is Principal Investigator of two grants from the National Institute on Drug Abuse (NIDA) (R01 DA03889 and R01 DA03890) and co-investigator on a contract and several other grants from NIDA. During the past 5 years, on issues about drug abuse liability, he has been a consultant to or received grants from the following pharmaceutical companies: Abbott Laboratories, Forest Laboratories Inc., Merck & Co., Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation, Orphan Medical, Pharmacia Corporation, Pfizer Inc., Takeda Pharmaceuticals, TransOral Pharmaceucticals, Inc., Somaxon Pharmaceuticals Inc., and Wyeth Pharmaceuticals. He has disclosed that he will be discussing non-medical use (ie, abuse) of various hypnotic drugs.

Topic Highlights

• Abuse Potential of Sleeping Agents: Liability Varies Among Agents
Insomnia: A Brief Review
Effects of Insomnia
Pharmacologic Treatment of Insomnia
Patterns of Sedative/Hypnotic Abuse

• Abuse Potential of Hypnotic Agents: Study Evaluates Relative Abuse Liability
Defining Relative Abuse Liability and Toxicity
Relative Abuse Liability Table
Results of Analysis

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.

A supplement to Internal Medicine News supported by a restricted grant from TAP Pharmaceutical Products, Inc.
Symposium Highlights of articles based on presentations given at a continuing medical education symposium held on May 19, 2002, in San Francisco, Calif.

To view the supplement, click the image above.

INTRODUCTION
Richard H. Hunt, FRCP, FRCP(C), FACG
Professor of Medicine
McMaster University Medical Centre
Hamilton, Ont.
Consultant: Abbott Laboratories, Axcan Pharma Inc., AstraZeneca, Merck & Co., Novartis Pharmaceuticals Corp., Procter & Gamble Co., TAP Pharmaceutical Products, Inc.; Investigator: Axcan, AstraZeneca, Merck, TAP.

USE OF NONSELECTIVE NSAIDS, CYCLOOXYGENASE INHIBITORS, AND PROTON PUMP INHIBITORS
Treat With Nonselective NSAIDs, plus PPIs
Michael B. Kimmey, MD
Professor of Medicine and Director of Gastrointestinal Endoscopy
University of Washington
Seattle, WA
Nothing to disclose.

Treat With Cyclooxygenase Inhibitors
Jay L. Goldstein, MD
Professor of Medicine
Vice Head for Clinical Affairs
Department of Medicine
University of Illinois
Chicago, IL
Consultant & Grant Support: AstraZeneca, Pharmacia Corp., Pfizer Inc., TAP.

OPTIONS IN THE LONG-TERM MAINTENANCE OF GASTROESOPHAGEAL REFLUX DISEASE
Endoscopic/Surgical Intervention
George Triadafilopoulos, MD
Professor of Medicine
Stanford University School of Medicine
Chief, Section of Gastroenterology
Palo Alto Veterans Affairs Health Care System
Palo Alto, CA
Consultant: Curon Medical Inc., TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Curon, Janssen, TAP, Wyeth; Equity: Curon.

Management on Long-Term PPI Therapy
Colin W. Howden, MD, FACG
Professor of Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL
Consultant: Prometheus, Takeda Pharma, TAP; Investigator: TAP, Merck; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Merck, TAP, Wyeth.

IS SCREENING FOR BARRETT'S ESOPHAGUS NECESSARY?
Good Evidence for Screening
Roy K.H. Wong, MD, FACG
Professor of Medicine
Director of the Division of Digestive Diseases
Uniformed Services University of the Health Sciences
Bethesda, MD
Grant Support: ACG, AstraZeneca, Janssen.

Screenings Not Cost-Effective
Dawn Provenzale, MD
Associate Professor & Director of GI Outcomes Research
Duke University Medical Center
Durham, N.C.
Nothing to disclose.

ENDOSCOPY-NEGATIVE REFLUX DISEASE: ACID-RELATED DISORDER OR FUNCTIONAL DISORDER?
Endoscopy-Negative Reflux Disease Is an Acid-Related Disorder
Joel E. Richter, MD
Professor of Medicine and Chairman
Department of Gastroenterology and Hepatology
Cleveland Clinic Foundation
Cleveland, OH
Consultant: AstraZeneca, TAP; Speakers' Bureau: AstraZeneca, Janssen, TAP, Wyeth.

Endoscopy-Negative Reflux Disease Is a Functional Disorder
William D. Chey, MD, FACG, FACP
Associate Professor of Medicine
Director of GI Physiology Laboratory
University of Michigan
Ann Arbor, MI
Consultant: AstraZeneca, TAP; Grant Support: AstraZeneca; Speakers' Bureau: AstraZeneca, Janssen Pharmaceutica, Inc., TAP.

A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.

To view the supplement, click the image above.

CLINICAL EDITORIALS
Early Defibrillation: A Critical Link in the Chain of Survival
Lance B. Becker, MD
Professor of Clinical Medicine
Department of Medicine
The University of Chicago
Chicago, Ill.
Clinical Grants and Consultant: Philips

Advances in Defibrillator Technology
Gust H. Bardy, MD
Clinical Assistant Professor, Medicine/Cardiology
University of Washington
Medical Center
Seattle, Wash.
Clinical Grants and Consultant: Philips

EXPERT PANEL DISCUSSION
Improving Survival From Sudden Cardiac Arrest: Is it Time for Home Defibrillators?
Howard A. Torman, MD
Consultant
New York, NY
Nothing to disclose.

Sherry Caffrey
Director, Chicago HeartSave™
Training Coordinator
Chicago Airport System
Chicago, Ill.
Consultant: Philips

Arthur L. Kellermann, MD, MPH
Professor and Chair
Department of Emergency Medicine
Emory University School of Medicine
Atlanta, Ga.
Nothing to disclose.

Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.

Edward M. Racht, MD
Medical Director
Austin/Travis County
Emergency Medical Service
Austin, Tex.
Nothing to disclose.

A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.

To view the supplement, click the image above.

CLINICAL EDITORIALS
Early Defibrillation: A Critical Link in the Chain of Survival
Lance B. Becker, MD
Professor of Clinical Medicine
Department of Medicine
The University of Chicago
Chicago, Ill.
Clinical Grants and Consultant: Philips

Advances in Defibrillator Technology
Gust H. Bardy, MD
Clinical Assistant Professor, Medicine/Cardiology
University of Washington
Medical Center
Seattle, Wash.
Clinical Grants and Consultant: Philips

EXPERT PANEL DISCUSSION
Improving Survival From Sudden Cardiac Arrest: Is it Time for Home Defibrillators?
Howard A. Torman, MD
Consultant
New York, NY
Nothing to disclose.

Sherry Caffrey
Director, Chicago HeartSave™
Training Coordinator
Chicago Airport System
Chicago, Ill.
Consultant: Philips

Arthur L. Kellermann, MD, MPH
Professor and Chair
Department of Emergency Medicine
Emory University School of Medicine
Atlanta, Ga.
Nothing to disclose.

Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.

Edward M. Racht, MD
Medical Director
Austin/Travis County
Emergency Medical Service
Austin, Tex.
Nothing to disclose.

A supplement to Internal Medicine News, supported by an unrestricted educational grant from Philips.
Highlights developed from physician interviews and from a panel discussion held in Washington, D.C., on January 30, 2002.

To view the supplement, click the image above.

CLINICAL EDITORIALS
Early Defibrillation: A Critical Link in the Chain of Survival
Lance B. Becker, MD
Professor of Clinical Medicine
Department of Medicine
The University of Chicago
Chicago, Ill.
Clinical Grants and Consultant: Philips

Advances in Defibrillator Technology
Gust H. Bardy, MD
Clinical Assistant Professor, Medicine/Cardiology
University of Washington
Medical Center
Seattle, Wash.
Clinical Grants and Consultant: Philips

EXPERT PANEL DISCUSSION
Improving Survival From Sudden Cardiac Arrest: Is it Time for Home Defibrillators?
Howard A. Torman, MD
Consultant
New York, NY
Nothing to disclose.

Sherry Caffrey
Director, Chicago HeartSave™
Training Coordinator
Chicago Airport System
Chicago, Ill.
Consultant: Philips

Arthur L. Kellermann, MD, MPH
Professor and Chair
Department of Emergency Medicine
Emory University School of Medicine
Atlanta, Ga.
Nothing to disclose.

Richard A. Lazar, Esq.
President/CEO
Fios, Inc.
Portland, Ga.
Nothing to disclose.

Edward M. Racht, MD
Medical Director
Austin/Travis County
Emergency Medical Service
Austin, Tex.
Nothing to disclose.

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action

A supplement to Family Practice News and Internal Medicine News.
This Journal Scan is supported by 3M Pharmaceuticals.

•Introduction
•Topic Highlights

To view the supplement, click the image above.

Introduction
Thomas J. Zuber, MD, MPH, MBA
Adjunct Associate Professor
Brody School of Medicine, East Carolina University
Private Practice, Mountain Family Medicine
Boone, North Carolina
Nothing to disclose.

Topic Highlights

• Condyloma Recurrence Rates Improve With Immune Response Modifier Treatment

• 3-Year Experience With Imiquimod in Vulvar Warts

• Placebo-Controlled Trial in External Anogenital Warts

• Phase III Trials of Imiquimod in Actinic Keratosis

• Observational Long-Term Study of Imiquimod in Actinic Keratosis

• Immune Response Modifier Mechanism of Action